GlassScriptPhysician profile
Joseph Lennartz
NPI 1225606742
$8,257.15
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,125 · 2022: $1,956 · 2023: $2,695 · 2024: $2,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134 · Consulting Fee: $1,075 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.68 |
| Consulting Fee | $1,075.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $967.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,949.20 | 2022-2024 | Senza, Omnia |
| Dexcom, INC. | $861.27 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $851.08 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $815.04 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $252.65 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.23 | 2021-2024 | Jardiance |
| Amgen INC. | $234.53 | 2022-2024 | Repatha, Prolia, Evenity |
| Xeris Pharmaceuticals, INC. | $209.17 | 2022-2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $200.03 | 2022-2024 | |
| Antares Pharma, INC. | $191.40 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $175.60 | 2021-2023 | |
| Ibsa Pharma INC. | $169.87 | 2022-2024 | Tirosint, Licart, Licart |
| Amarin Pharma, INC. | $155.79 | 2021-2022 | |
| Medtronic, INC. | $102.24 | 2022-2023 | Vanta Adaptivestim, Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $101.44 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $101.16 | 2021-2024 | Afrezza |
| Amneal Pharmaceuticals LLC | $95.63 | 2021 | |
| Recordati_rare_diseases_inc. | $91.64 | 2023 | Isturisa, Signifor Lar |
| Esperion Therapeutics, INC. | $72.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $64.58 | 2021 | |
| Abbvie INC. | $47.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $41.19 | 2022 | |
| Sequel Med Tech, LLC | $34.93 | 2024 | |
| Averitas Pharma INC. | $33.62 | 2023 | Qutenza |
| Tandem Diabetes Care, INC. | $23.74 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Embecta Corp. | $21.03 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Halozyme INC | $20.34 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $19.34 | 2024 | Imcivree |
| Amphastar Pharmaceuticals, INC. | $17.28 | 2023 | Baqsimi |
| Acella Pharmaceuticals, LLC | $17.28 | 2023 | NP Thyroid 60 |
| Ascensia Diabetes Care US INC. | $16.70 | 2022 | |
| Corcept Therapeutics | $15.60 | 2021 | |
| Amryt Pharma Holdings LTD | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lennartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.